

## Drug Class Review Monograph – GPI Class 54 – Urinary Antispasmodics

Review Time Frame: 02/2016 – 01/2017

Previous Class Review: 08/2016

### Background:

Urinary antispasmodics are agents used for the treatment of urinary incontinence, ~~or the involuntary leakage of urine, and~~ overactive bladder (OAB), ~~or urinary retention.~~ ~~They~~ ~~Pharmacologic therapies for urinary incontinence and overactive bladder~~ include:

- Antimuscarinics, which act primarily by increasing bladder capacity and decreasing urgency by blocking basal release of acetylcholine during bladder filling;
- Beta 3-adrenergic agonists, which activates beta-3 adrenergic receptors, relaxing the detrusor smooth muscle during the storage phase of the urinary bladder fill-void cycle which increases bladder capacity;
- Cholinergic agonists, which stimulate muscarinic receptors in the bladder to contract the detrusor, decreasing bladder capacity and producing urination; and
- Direct muscle relaxants, which relax smooth muscles of the urinary tract (i.e., the detrusor muscle) thereby reducing symptoms associated with bladder spasticity.

Formatted: Font: Not Bold

Formatted: Font: Not Bold

### New treatment guideline recommendations:

- ~~None identified new treatment guideline recommendations identified.~~

Formatted: Font: Bold

### Newly approved drugs:

- None identified

### Newly approved formulations:

- None identified

### Newly approved generics:

- ~~Darifenacin Extended Release tablets, 7.5mg and 15mg (Enablex) on 3/13/2015~~
  - ~~Note: Generic version of Enablex is not commercially available at this time.~~
- ~~Fesoterodine Extended Release tablets, 4mg and 8mg (Toviaz) on 12/10/15~~
  - ~~Note: Generic version of Toviaz is not commercially available at this time.~~
- None identified

### Discontinued drugs:

- None identified

### FDA Safety Alerts/black box warnings:

- None identified

### Pipeline alerts:

Agents pending FDA approval include:

- None identified

### References:



Formatted: Right

1. Lukacz ES. Treatment of urinary incontinence in women. Brubaker L, Schmader KE. (Ed), UpToDate. Waltham MA. Accessed January 2017~~6~~.
2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; ~~2015~~2017. URL: <http://www.clinicalpharmacology-ip.com/>. ~~Updated~~ ~~Accessed~~ January 2017~~6~~.
3. US Script Oracle PBM: Medi-Span® Master Drug Data Base. January 2017~~6~~.
4. Food and Drug Administration. Available at: [WWW.FDA.GOV](http://WWW.FDA.GOV).